Maze Therapeutics (MAZE) grants GC 32k options and 16k RSUs

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Courtney Phillips reported acquisition or exercise transactions in this Form 4 filing.

Maze Therapeutics, Inc. reported that its General Counsel and Corporate Secretary, Courtney Phillips, received equity awards consisting of stock options and restricted stock units. The grant covers 32,000 options that vest monthly over four years starting on April 1, 2026, and 16,000 RSUs that vest annually in four equal installments beginning on March 1, 2027, in each case conditioned on continued service.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Courtney Phillips

Role GC and Corp. Secretary

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	32,000	$0.00	--
Grant/Award	Restricted Stock Units	16,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 32,000 shares (Direct); Restricted Stock Units — 16,000 shares (Direct)

Footnotes (1)

The option award shall vest as to 1/48 of the total award monthly, with the first tranche vesting on April 1, 2026, subject to the reporting person's continued service to the Issuer on each vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The restricted stock unit award shall vest in ratable increments of 1/4 of the total award, with the first tranche vesting on March 1, 2027, and vesting thereafter on the one year anniversary of such date, subject to the reporting person's continued service to the Issuer on each vesting date. These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date.

Form 4 Insider Transactions: What Each Field Means →

03/03/2026 - 04:28 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Courtney Phillips

(Last)

(First)

(Middle)

C/O MAZE THERAPEUTICS, INC.

171 OYSTER POINT BOULEVARD, SUITE 300

(Street)

SOUTH SAN FRANCISCO

94080

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	GC and Corp. Secretary

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$45.61	03/02/2026		A		32,000		⁽¹⁾	03/01/2036	Common Stock	32,000	$0	32,000	D
Restricted Stock Units	⁽²⁾	03/02/2026		A		16,000		⁽³⁾	⁽⁴⁾	Common Stock	16,000	$0	16,000	D

Explanation of Responses:

1. The option award shall vest as to 1/48 of the total award monthly, with the first tranche vesting on April 1, 2026, subject to the reporting person's continued service to the Issuer on each vesting date.

2. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.

3. The restricted stock unit award shall vest in ratable increments of 1/4 of the total award, with the first tranche vesting on March 1, 2027, and vesting thereafter on the one year anniversary of such date, subject to the reporting person's continued service to the Issuer on each vesting date.

4. These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date.

	/s/ Courtney Phillips	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Maze Therapeutics (MAZE) report for Courtney Phillips?

Maze Therapeutics reported that General Counsel Courtney Phillips received 32,000 stock options and 16,000 restricted stock units. The options vest monthly over four years, while the RSUs vest in four annual installments, all contingent on continued service with the company.

How many stock options were granted to Maze Therapeutics (MAZE) General Counsel?

Courtney Phillips was granted 32,000 stock options at an exercise price of $0.00 per share. These options vest as to 1/48 of the total award each month, starting on April 1, 2026, subject to her continued service with Maze Therapeutics.

What restricted stock unit award did Maze Therapeutics (MAZE) grant on March 2, 2026?

Maze Therapeutics granted 16,000 restricted stock units on March 2, 2026. Each RSU represents a contingent right to receive one share of common stock, vesting in four equal annual installments starting March 1, 2027, provided Courtney Phillips continues serving the company on each vesting date.

When do the Maze Therapeutics (MAZE) stock options for Courtney Phillips vest?

The 32,000 stock options begin vesting on April 1, 2026, in monthly installments of 1/48 of the total award. Full vesting occurs over four years, assuming Courtney Phillips remains in continuous service with Maze Therapeutics through each monthly vesting date.

How do Maze Therapeutics (MAZE) restricted stock units for Courtney Phillips vest?

The 16,000 RSUs vest in four equal 25% tranches, with the first vesting on March 1, 2027. Subsequent portions vest on each one-year anniversary of that date, as long as Courtney Phillips continues providing service to Maze Therapeutics at each vesting point.

Do Maze Therapeutics (MAZE) restricted stock units for Courtney Phillips expire?

The restricted stock units do not carry an expiration date. They either vest according to the scheduled four annual installments starting March 1, 2027, or are cancelled before the relevant vesting date if the required continued service condition is not met.